Form 4: Vericel COO Halpin Reports RSU Vesting, Tax Withholding

Vericel Corp's Chief Operating Officer, Michael Halpin, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Summary

• Michael Halpin, Chief Operating Officer of Vericel Corp (VCEL), reported transactions related to the vesting of Restricted Stock Units (RSUs).
• On February 24, 2026, 5,250 shares of common stock were acquired due to the vesting of RSUs granted on February 20, 2025.
• Concurrently, 2,486 shares were disposed of to satisfy tax withholding requirements related to this vesting, at a price of $38.09 per share.
• An additional 5,250 shares of common stock were acquired on February 24, 2026, from the vesting of RSUs granted on February 22, 2024.
• Another 2,486 shares were disposed of for tax withholding purposes related to this second vesting event, at a price of $38.25 per share.
• Following these transactions, Michael Halpin directly beneficially owns 26,385 shares of Vericel Corp common stock.
• Remaining RSUs from the February 20, 2025 grant will vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029.
• Remaining RSUs from the February 22, 2024 grant will vest in annual installments on February 22, 2027, and February 22, 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine and expected executive compensation transaction with no material impact on the company's operational or financial outlook.

Positives

• The vesting of Restricted Stock Units (RSUs) represents a routine component of executive compensation, aligning management's interests with long-term shareholder value.
• The continued vesting schedule for remaining RSUs indicates ongoing equity incentives for the Chief Operating Officer.

Negatives

• A portion of the vested shares was sold to cover tax withholding obligations, which is a standard practice but results in a reduction of direct share ownership.

Future Outlook

Remaining Restricted Stock Units (RSUs) granted on February 20, 2025, are scheduled to vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029. Additionally, RSUs granted on February 22, 2024, will vest in annual installments on February 22, 2027, and February 22, 2028.

Industry Context

StockSavvy.ai notes that this Form 4 filing details a routine insider transaction, specifically the vesting of Restricted Stock Units (RSUs) and the subsequent sale of shares to cover tax obligations. This is a common and standard practice in executive compensation across various industries, including biotechnology and pharmaceuticals, designed to align executive incentives with long-term shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting of restricted stock units and subsequent sale of shares for tax purposes is a standard and widely adopted practice in executive compensation across various industries, including biotechnology and pharmaceuticals, aligning executive incentives with shareholder value creation.
• This type of transaction is consistent with typical equity compensation structures seen in publicly traded companies, where executives receive performance-based or time-based equity awards that vest over several years.

Stakeholder Impact

• Shareholders: Minimal, routine impact as these are standard executive compensation events. The slight dilution from RSU vesting is typically factored into valuation models.
• Employees: No direct impact on general employees, but it reinforces the company's executive compensation structure.

Next Steps

• Future annual vesting of remaining RSUs granted on February 20, 2025, on February 20, 2027, February 20, 2028, and February 20, 2029.
• Future annual vesting of remaining RSUs granted on February 22, 2024, on February 22, 2027, and February 22, 2028.

Key Dates

Recommendation

This filing reports routine executive compensation events (RSU vesting and tax-related share sales) for Vericel Corp's Chief Operating Officer. It does not contain new material information that would alter an investment thesis or warrant a change in an existing 'hold' recommendation for the stock.

Keywords

Vericel, VCEL, Form 4, RSU vesting, insider transaction, executive compensation, Michael Halpin, stock disposition